The FDA on January 19, 2023, approved BRUKINSA® for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). BRUKINSA® is a product of BeiGene USA, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement